Castlight health, inc. (CSLT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

-56,335

-11,746

-9,336

-8,381

-10,539

-4,039

-7,265

-13,958

-14,444

-7,157

-17,992

-12,379

-14,374

-9,236

-11,403

-16,692

-21,355

-19,058

-20,007

-21,212

-19,643

-19,684

-20,199

-21,776

-24,281

-19,973

-16,603

-14,173

-11,433

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,535

1,552

1,681

1,343

1,344

1,587

1,698

1,713

1,860

2,041

1,814

2,060

698

761

822

802

783

646

468

456

454

410

340

322

282

232

188

113

100

Goodwill impairment

50,300

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

3,186

3,156

3,013

4,857

3,977

4,123

4,270

5,147

4,592

-

-

-

-

5,001

5,652

5,109

5,494

4,785

4,959

4,217

3,869

4,599

4,109

2,940

2,553

1,054

530

465

378

Amortization and impairment of deferred commissions

2,383

-

2,547

2,365

2,491

-

3,217

2,947

2,853

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization and impairment of deferred professional service costs

925

2,132

1,096

1,045

969

1,917

1,254

1,151

946

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash operating lease expense

1,400

-

1,339

1,298

1,282

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of deferred commissions

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,042

953

1,162

934

917

802

857

973

875

868

1,376

1,800

416

196

129

Lease exit and related charges

-

-

-

-

-

564

253

901

916

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Release of deferred tax valuation allowance due to business combination

-

-

-

-

-

-

-

-

-

-

0

5,142

64

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion and amortization of marketable securities

-2

-6

31

87

126

124

126

135

131

-

-

-

-

-75

-101

-129

-176

-259

-299

-384

-443

-468

-524

-373

-124

-129

-164

-193

-228

Expense related to expiration of SAP warrant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20

160

70

2,429

135

0

0

0

Changes in operating assets and liabilities:
Accounts receivable and other, net

6,676

-4,045

2,831

-2,088

7,883

-3,419

2,050

-4,944

11,196

-4,979

4,661

4,808

-1,691

-859

3,397

-1,542

1,282

-894

2,597

560

-609

-181

886

4,077

1,250

1,355

-39

1,412

-25

Deferred commissions

318

841

1,833

1,254

1,416

555

2,201

1,808

1,171

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred professional service costs

416

385

400

432

469

625

721

647

742

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,479

-2,635

-289

-4,287

-1,595

-1,113

-638

-1,235

-2,257

-1,087

-282

-1,658

-2,034

-700

-567

Prepaid expenses and other assets

494

-924

-1,042

1,113

751

-1,297

-777

2,102

-206

-2,038

-466

2,042

-1,183

-516

-745

849

-36

-1,354

-792

1,848

-30

-27

245

596

1,081

-18

-265

435

100

Accounts payable

-7,462

6,900

514

2,713

-849

3,999

1,234

-1,272

1,783

363

909

-685

177

-1,335

410

-715

605

-70

-542

-254

1,512

-46

-191

-375

759

640

-51

849

-570

Operating lease liabilities

-1,516

9,993

-1,472

-1,413

-1,382

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other liabilities

19

-688

59

-1,827

-1,304

-1,355

-1,537

4,419

-1,237

-

-

-

-4,755

5,789

-3,583

3,269

-3,732

582

1,429

1,234

-4,403

-883

3,956

2,173

-3,376

-55

1,838

2,406

-1,297

Deferred revenue

3,573

-7,588

-3,202

-3,183

3,495

-6,904

-1,105

-4,393

3,183

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,733

-2,827

4,412

982

1,367

682

3,721

1,254

6,356

1,591

6,686

1,936

1,886

2,493

953

Accrued compensation

-4,465

3,223

378

164

-970

114

-3,669

1,979

-6,390

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-14,359

3,992

-7,436

-1,817

-12,131

7,506

-5,971

-1,114

-18,972

-80

-8,351

-4,114

-10,912

-1,710

-9,357

-11,914

-13,990

-11,957

-14,510

-17,212

-13,189

-11,544

-7,458

-19,574

-16,061

-14,543

-13,362

-10,005

-12,154

Investing activities:
Purchase of property and equipment

1,264

1,241

119

389

204

119

591

916

388

268

1,346

1,096

-166

115

345

776

466

1,877

1,806

806

887

462

431

311

656

308

1,161

408

710

Purchase of marketable securities

1,989

7,520

9,289

13,780

0

6,544

1,451

13,954

10,025

5,806

25,077

47,782

-16,007

25,021

11,971

31,706

29,486

33,543

67,366

5,924

13,034

19,928

48,213

126,442

35,733

0

25,808

8,382

8,098

Sales of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,000

0

0

0

13,000

0

0

0

5,000

Maturities of marketable securities

12,400

11,075

3,217

0

11,453

16,860

9,900

10,700

15,750

-

-

-

34,799

20,351

35,570

31,950

58,637

40,092

78,466

31,373

30,180

22,762

45,765

3,000

5,000

13,300

14,760

39,075

5,000

Net cash provided by investing activities

9,147

2,314

-6,191

-14,169

11,249

10,197

7,858

-4,170

5,337

15,369

-9,527

10,142

18,626

-4,785

23,254

-532

28,685

5,672

8,294

20,518

21,259

2,372

-2,879

-123,652

-18,389

12,992

-12,209

30,285

1,192

Financing activities:
Proceeds from exercise of stock options

155

1,136

79

165

1,680

1,867

371

1,752

490

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from ESPP offering

186

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

374

-

-

-

-

764

354

1,186

1,640

1,366

300

106

1,522

550

114

154

46

Proceeds from the issuance of common stock and warrants to SAP

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

16,092

1,266

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on long-term debt

465

465

464

465

465

465

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,781

-3,781

0

189,943

0

0

0

0

Payments of issuance costs related to equity

-

-

-

-

-

-

-

-

-

0

0

1,343

-612

0

76

46

0

0

0

0

94

3,781

-3,781

1,679

2,102

-

-

-

-

Net cash (used in) provided by financing activities

-124

671

-385

-300

1,215

1,402

371

1,752

490

1,044

481

338

-238

253

560

17,986

1,266

764

354

1,186

1,546

1,366

300

-1,573

189,363

110

114

154

46

Net (decrease) increase in cash, cash equivalents and restricted cash

-5,336

6,977

-14,012

-16,286

333

19,105

2,258

-3,532

-13,145

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents and restricted cash:
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,457

5,540

15,961

-

-5,862

4,492

9,616

-7,806

-10,037

-144,799

154,913

-1,441

-25,457

20,434

-10,916